Eli Lilly and Company LLY is facing growing pressure from India's fast-expanding generics market. Lower-cost versions of its ...

Eli Lilly and Co. has entered into an agreement with India-based drugmaker Cipla to sell its blockbuster weight-loss drug, tirzepatide, under a different brand name, the company announced Thursday.

The global fight between Eli Lilly and Novo Nordisk for dominance in the red-hot weight-loss drug market is shifting to India, one of the fastest-growing pharmaceutical frontiers. As rising obesity ...

June 20 (Reuters) - Eli Lilly (LLY.N), opens new tab said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the ...

Cipla collaboration brings a second brand of tirzepatide, Yurpeak, to India, aiming to widen patient access for diabetes and ...

June 26 (Reuters) - India's drug regulator on Thursday approved the launch of pre-filled injector pens of Eli Lilly's (LLY.N), opens new tab blockbuster weight-loss drug, Mounjaro, giving the company ...

HYDERABAD, Feb 17 (Reuters) - Mounjaro-maker Eli Lilly wants to turn India into a hub for its global supply chain, a senior executive ‌at the U.S. drugmaker said, as part of its previously committed ...

HYDERABAD, India, Dec 24 (Reuters) - Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market before cheaper generic versions hit ...